Social Anxiety Disorder Study Of Paroxetine

Phase 3

Completed

• Conditions: Social Phobia

• Registration Number: NCT00318669
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2005-12
• Study First Submitted: 2006-04-25
• Study First Submitted QC: 2006-04-25
• Study First Posted: 2006-04-27
• Primary Completion: 2006-11
• Study Completion: 2006-11
• Status Verified: 2012-07
• Last Update Submitted: 2013-04-11
• Last Update Posted: 2013-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 390

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change from baseline in the LSAS total score at week 12 (Score at week 12 - Score at week 0)	12 Weeks

Secondary Outcome Measures

Name	Time	Method
Proportion of patients responding with a CGI Global Improvement Item score. Change from baseline in the CGI Severity of Illness score. Change from baseline in the HAM-D total score. Proportion of patients continuing treatment.	12 Weeks

Trial Locations

Locations (1)

GSK Investigational Site